CytomX Therapeutics (CTMX) to Release Earnings on Thursday

Posted by Tech Dows on Nov 6th, 2024

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

CytomX Therapeutics (NASDAQ:CTMX – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $25.12 million for the quarter, compared to analysts’ expectations of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. During the same quarter in the previous year, the company posted ($0.02) earnings per share. On average, analysts expect CytomX Therapeutics to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

CytomX Therapeutics Trading Down 1.7 %

CytomX Therapeutics stock opened at $0.99 on Wednesday. The firm’s 50 day simple moving average is $1.15 and its 200 day simple moving average is $1.48. The firm has a market capitalization of $77.57 million, a PE ratio of 7.09 and a beta of 1.06. CytomX Therapeutics has a 1-year low of $0.99 and a 1-year high of $5.85.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $5.77.

Check Out Our Latest Stock Report on CTMX

CytomX Therapeutics Company Profile

(Get Free Report)

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.